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PURPOSE. Biallelic mutations in AIPL1 cause Leber congenital amaurosis (LCA), a devastating
retinal degeneration characterized by the loss or severe impairment of vision within the first
few years of life. AIPL1 is highly polymorphic with more than 50 mutations and many more
polymorphisms of uncertain pathogenicity identified. As such, it can be difficult to assign
disease association of AIPL1 variations. In this study, we investigate suspected disease-
associated AIPL1 variations, including nonsynonymous missense and intronic variants to
validate their pathogenicity.
METHODS. AIPL1 minigenes harboring missense and intronic variations were constructed by
amplification of genomic fragments of the human AIPL1 gene. In vitro splice assays were
performed to identify the resultant AIPL1 transcripts.
RESULTS. We show that all nine of the suspected disease-associated AIPL1 variations
investigated induced aberrant pre-mRNA splicing of the AIPL1 gene, and our study is the
first to show that AIPL1missense mutations alter AIPL1 splicing. We reveal that the presumed
rare benign variant c.784G>A [p.(G262S)] alters in vitro AIPL1 splicing, thereby validating
the disease-association and clarifying the underlying disease mechanism. We also reveal that
in-phase exon skipping occurs normally at a low frequency in the retina, but arises abundantly
as a consequence of specific AIPL1 variations, suggesting a tolerance threshold for the
expression of these alternative transcripts in the retina normally, which is exceeded in LCA.
CONCLUSIONS. Our data confirm the disease-association of the AIPL1 variations investigated and
reveal for the first time that aberrant splicing of AIPL1 is an underlying mechanism of disease
in LCA.
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Leber congenital amaurosis (LCA) is the most severeinherited retinal degeneration and the most common cause
of congenital blindness.1 Leber congenital amaurosis is
diagnosed in infancy and is characterized by a severely reduced
or nonrecordable ERG. Leber congenital amaurosisis is genet-
ically heterogeneous and typically inherited in an autosomal
recessive manner with more than 19 genes reported to be
involved (Retinal Information Network), including AIPL1.2
The AIPL1 gene is comprised of six exons coding for the
Aryl Hydrocarbon Receptor Interacting Protein-Like 1. AIPL1 is
a photoreceptor-specific molecular cochaperone that interacts
specifically with the molecular chaperone HSP90 to modulate
the stability and assembly of the HSP90 substrate, retinal cGMP
phosphodiesterase (PDE6).3–5
Presently, the Human Gene Mutation Database (HGMD)
records 52 AIPL1 mutations.6 Several of these AIPL1 mutations
are known benign single nucleotide polymorphisms (SNPs),
while several others can be reclassified as benign rare variants
in the light of recent evidence, including the detection of these
sequence variations in the homozygous state in unaffected
control populations.7,8 A number of AIPL1 nonsynonymous
missense sequence variations reported as LCA-associated, but
not recorded in the HGMD, are of uncertain pathogenicity.7
Moreover, several hundred AIPL1 sequence variations of
different functional classes are reported throughout the AIPL1
gene in the Single Nucleotide Polymorphism Database (dbSNP).
Ascribing the disease-causing status of LCA-associated AIPL1
sequence variations is therefore a challenge confounded by the
polymorphic nature of the gene. Confirmation of disease-
associated AIPL1 variations is important for patient diagnosis,
counselling, and potential treatments, with the main therapeu-
tic strategy currently focusing on AIPL1-targeted gene replace-
ment therapy.
Thorough in vitro investigations are necessary to differen-
tiate true disease-associated variations from rare polymor-
phisms. The functional consequences of only a handful of
missense and nonsense changes in the AIPL1 coding sequence
have been investigated by introducing the variation in the
cDNA sequence and testing the impact on protein func-
tion.4,9–14 These assays have primarily investigated the conse-
quences of AIPL1 variations on domain-mediated AIPL1 protein
interactions. The AIPL1 carboxy-terminal tetratricopeptide
repeat (TPR) domain mediates the interaction with the
molecular chaperone HSP90.4 The AIPL1 amino-terminal
FK506 binding protein (FKBP)-like domain interacts directly
with a farnesyl motif in vitro and is therefore predicted to
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interact with the farnesylated alpha subunit of retinal PDE6.14
A number of in vitro functional studies investigating AIPL1
domain-dependent interactions,4,9–11,14 have proven useful in
validating disease-causing AIPL1 mutations and understanding
the role of AIPL1 as an HSP90 cochaperone for retinal PDE6.
In contrast, the effects of noncoding variations in AIPL1 are
unknown, and missplicing of AIPL1 as an underlying disease
mechanism has not been experimentally investigated. In this
study, we investigated missense and intronic AIPL1 variations
identified in LCA patients that are predicted to alter AIPL1 pre-
mRNA splicing. We determined the outcome of the variations
on AIPL1 splicing and confirm that aberrant alternative
transcription of AIPL1 could be an underlying cause of LCA.
MATERIALS AND METHODS
AIPL1 Sequence Variations and Nomenclature
AIPL1 sequence variations detected in previously genotyped
LCA patients were investigated in this study.7,15,16 The AIPL1
sequence variations investigated were selected on the basis
that the disease-causing status was either unknown or
uncertain,7 and on the basis that we had previously
performed clinical investigations of the patients harboring
the AIPL1 variations.7,16 The study was conducted in
accordance with the tenets of the Declaration of Helsinki
and approved by the Moorfields and Whittington Hospitals’
local ethics committee. Ensembl and UCSC Genome Browsers
were used for analyses of the Human GRCh37/hg19 (February
2009) and GRCh38/hg38 (December 2013) assemblies. The
AIPL1 cDNAs are numbered according to the Ensembl
Transcript ENST00000381129 (RefSeq NM_014336,
NP_055151). Complementary DNA nucleotide numbering
uses þ1 as the ATG translation initiation codon in the
reference sequence, with the initiation codon as codon 1.
The coordinates for the genomic AIPL1 sequence used are
chr17:6,327,059-6,338,519 (hg19) and chr17:6,423,737-
6,435,185 (hg38). Nomenclature was according to HGVS
standards.17
AIPL1 In Silico Analysis
AIPL1 variations were analyzed using three in silico software
prediction programmes: SIFT (Sorting Intolerant From Toler-
ant; in the public domain, http://sift.jcvi.org),18 PolyPhen-2
(Polymorphism Phenotyping v2; in the public domain, http://
genetics.bwh.harvard.edu/pph/index.html),19 and BLOSUM62
(Blocks Substitution Matrix; in the public domain, http://www.
uky.edu/Classes/BIO/520/BIO520WWW/blosum62.htm). In
silico analysis of splice-site confidence levels was performed
with the NetGene2 server (in the public domain, http://www.
cbs.dtu.dk/services/NetGene2/)20,21 and the Berkeley Dro-
sophila Genome Project Neural Network splice site prediction
algorithm NNSPLICE (in the public domain, http://www.
fruitfly.org/seq_tools/splice.html)22 using default settings.
Construction of Minigenes
Primers were designed to amplify genomic fragments of the
human AIPL1 gene. Restriction sites were added to the 50end
of the primers such that the amplified product could be
directionally cloned into the pBK-CMV expression vector
(Agilent Technologies, Waldbronn, Germany). The 50 end of
each minigene was cloned into the BmtI (NheI) site, thereby
deleting the lac promoter, while the corresponding 30 ends
were cloned into either the XhoI or NotI site.
Three AIPL1 minigenes were constructed. Minigene 1
encompasses exons 1 through 4 and excludes the start codon
to lessen the potential effects of nonsense-mediated decay
(NMD). This minigene was amplified in two fragments that
were cloned sequentially into pBK-CMV. Fragment 1 primers
were designed to amplify a 1418 bp fragment and tagged with
e i t he r Nhe I o r Sa l I : A I P L1_Ex1_1F, 5 0- g c t a gc
GATGCCGCTCTGCTCCTGAACGTGGAAG-3 0 and AI
PL1_Int2_1R, 50-gtcgacACTCCTGCTGGTCATAGCCCTGCTCC-
3.0 Fragment 2 primers were designed to amplify a 2126 bp
fragment and were tagged with either SalI or NotI:
AIPL1_Int2_1F, 5 0-gtcgacCAGCACTGCCAGGACACCAA
AGCGACTCTCTTGG - 3 0 a nd A I P L 1 _ Ex4_ 1R , 5 0-
gcggccgcTTGGTCTGCAGGTTCCTTAGGCAGATGATGG-3. 0
The SalI sites introduce an artificial junction to allow deletion
of approximately 4.7 kb of the central region of intron 2 of
AIPL1.
Minigene 2 encompasses exons 3-5. Primers were designed
to amplify an 1892 bp fragment and were tagged with either
BmtI or XhoI: AIPL1_Ex3_1F, 5 0-gctagcCACACGGGG
GTCTACCCCATCCTATCC-3 0 and AIPL1_Ex5_1R, 5 0-ctc
gagCTGGGTGGTGCCGGAGAATATCACTGGTGTGC-3. 0
Minigene 3 encompasses exons 4-6. Primers were designed
to amplify a 1693 bp fragment and were tagged with either
BmtI or XhoI: AIPL1_Int3_1F, 5 0-gctagcGGGGTCCCTGCC
TCACTGACCTGCAGC-3 0 and AIPL1_Ex6_3UTR_1R, 5 0-ctc
gagACCAGAAGTGACCAGGCCACTTGCTCC-3. 0
Genomic AIPL1 fragments were PCR amplified using Q5
Hot Start High-Fidelity 2X Master Mix (New England Biolabs,
Hitchin, UK) in 25-lL reactions containing 10 pmol of each
primer (Sigma-Aldrich, Dorset, UK) and 10 ng of genomic DNA,
with the following cycling conditions: Td ¼ 988C for 30
seconds, then 30 cycles of Td¼ 988C for 10 seconds, Ta¼728C
for 10 seconds, and Te¼728C for 60 seconds. Polymerase chain
reaction products were resolved on a 1.2% agarose gel (TAE
buffer). Amplicons were excised and gel purified (QIAquick
Gel Extraction Kit; QIAGEN, Crawley, UK), prior to cloning
into pSC-Bamp/kan (StrataClone Blunt PCR Cloning Kit;
Agilent Technologies). Sequence identity and integrity was
confirmed by direct Sanger sequencing. Where patient gDNA
was not readily available, mutations were engineered into w/t
alleles cloned in the pSB-Bamp/kan vector using site-directed
mutagenesis (SDM; Q5 Site-Directed Mutagenesis Kit; New
England Biolabs). Primers were designed using NEBaseChanger
software (in the public domain, http://nebasechanger.neb.
com), and SDM PCRs undertaken using suggested conditions.
For each mutation introduced by SDM, the entire allele was
sequenced to confirm mutation and sequence integrity.
Sequence verified AIPL1 fragments were cloned into pBK-
CMV using standard protocols (enzymes supplied by New
England Biolabs). Briefly, after digestion with appropriate
enzyme pairs, digestion products were separated on a 1.2%
agarose gel and relevant fragments excised, gel purified and
ligations prepared (T7 DNA Ligase). Ligations were trans-
formed into DH5a competent cells (New England Biolabs).
Completed expression constructs were sequence checked to
confirm mutational identity.
In Vitro Splice Assays
Minigenes were transfected into HEK293 cells plated at 2.53
105 cells/well in 6-well plates with TransIT-LT1 Transfection
Reagent (Cambridge BioScience for Mirus Bio LLC, Cambridge,
UK) following the manufacturer’s instructions. Twenty-four
hours post transfection, cells were rinsed twice with PBS and
total RNA extracted (RNeasy Mini Kit and QIAshredder,
QIAGEN) with on-column DNAse treatment (Promega, Hamp-
shire, UK). Poly-T primed cDNA was synthesized in 20-lL
volume from 2.5 lg of total RNA (Tetro cDNA Synthesis Kit,
Bioline Reagents Ltd., London, UK). Splice products were
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amplified from 1 lL of cDNA using the following primer pairs:
minigene 1, AIPL1_Ex1_1F and AIPL1_Ex4_1R - expected w/t
amplicon ¼ 652 bp; minigene 2, AIPL1_Ex3_1F and AI-
PL1_Ex5_1R - expected w/t amplicon ¼ 797 bp; minigene 3,
AIPL1_Int3_1F and AIPL1_Ex6_3UTR_1R - expected w/t
amplicon ¼ 520 bp. Polymerase chain reaction conditions
were similar to those used for minigene generation except that
the extension time was reduced to 10s/cycle. Polymerase chain
reaction products were resolved on 2% to 3% agarose gels.
Amplicons were excised, gel purified, cloned, and sequenced
as above. All sequence analysis was conducted using MacVec-
tor 11.1.2 (MacVector, Inc., Cary, NC, USA).
RNA-Seq Data Analysis
Publically available RNA-seq data from three healthy human
adult retinas23 was aligned against the hg19 reference genome.
Aligned reads were visualized using the Broad Institute
Integrated Genomics Viewer (IGV-2.3.40; Cambridge, MA,
USA).24,25 A Sashimi plot of AIPL1 mRNA sequencing reads
from each of the three retinas aligned to the reference genome
(human hg19) was generated to visualize differentially spliced
exons in normal retina. The transcript abundance was
estimated using the FPKM (fragments per kilo bases of exons
for per million mapped reads) normalization method.
RESULTS
In Silico Analysis of AIPL1 Variations
In silico analysis of the AIPL1 variations investigated indicates
that all are very rare (allele frequency < 1/10,000) and have
not been observed in the homozygous state in the current
Exome Aggregation Consortium (ExAC) data set (Table 1). Of
the three missense substitutions, the c.784G>A [p.(G262S)]
substitution appears to be the least damaging, being SIFT
tolerant and PolyPhen-2 benign. This is consistent with
previous in vitro studies that do not report a deficit in
[p.(G262S)] function compared with the wild-type protein.11
SIFT determines that the c.465G>T [p.(G155H)] and
c.642G>C [p.(K214N)] missense substitutions are damaging,
and neither are considered benign by PolyPhen-2 and
Blosum62. In silico analysis of the effect on splicing indicates
that all 9 AIPL1 variations have the potential to result in some
form of misspliced AIPL1 transcripts (Table 2). All AIPL1
variations are predicted to reduce or abolish native splice site
recognition leading to exon skipping, or in the case of
c.276þ2T>C and c.785-10_786del, the creation of potential
cryptic splice sites.
In Vitro Splicing Assay
We confirmed experimentally that AIPL1 could not be
amplified from total RNA purified from whole blood samples
from unaffected individuals (data not shown). Therefore, three
AIPL1 minigenes were constructed to investigate the splice
effects of the AIPL1 variations (Figs. 1A, 1B). The identity of
the indicated PCR fragments (Fig. 1C, bands 1–24) was
determined by sequence analysis (Supplementary Figs. S2–
S22). It can be seen from Figure 1C that the three w/t
constructs produced the cleanest PCR fragment profiles with
the fewest unique fragments, typically a strong splice product
of the expected size for minigene 1 (band 1), minigene 2 (band
16), and minigene 3 (band 19). For w/t minigene 1, in addition
to the expected PCR fragment (band 1), a smaller secondary
splice product (band 2) was also amplified (see below). All of
the minigenes carrying nucleotide variations exhibited PCR
fragment profiles that differed from the corresponding w/tT
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minigene. Polymerase chain reaction products were selected
for sequence analysis on the basis of size similarity to the w/t
product(s) and abundance. High molecular weight bands
greater than the expected size of the w/t product and present
in all samples, including the w/t control, were excluded from
analysis. The results of the in vitro splicing assay are
summarised in Table 3, which lists the band size (bp), a
detailed description of the corresponding observed splicing
effect (also see Supplementary Figs. S2–S22) and the predicted
protein product. The resultant splice products and their
predicted protein products are also depicted schematically in
Figures 2 and 3, respectively.
All three w/t constructs yield normally spliced RNA
products as their most abundant splice product. Interestingly,
w/t minigene 1 produces a second 463 bp splice product that
lacks exon 3 and translates to p.H93_Q155del (DEx3). The
p.H93_Q155del (DEx3) product encompasses an in-frame
deletion of 62 amino acids from the FKBP-like domain of
AIPL1 encompassing the region proposed to be critical for the
interaction of AIPL1 with the farnesyl moiety. We did not
observe exon skipping with the w/t minigene 2 and 3.
From Table 3, it can be seen that all the AIPL1 variations
investigated (with the exception of c.97_104dupGTGATCTT
and c.98_99insTGATCTTG) affect splicing such that the native
splice-site is not recognized, with either exon skipping,
activation of cryptic splice-sites, or intron retention occurring.
Partial recognition of the native splice-site in c.97_104dupGT-
GATCTT and c.98_99insTGATCTTG leads to premature trans-
lation termination resulting in p.F35Lfs*2 and p.I34Dfs*10,
respectively. Both mutations also induce a frame-shifted
prematurely terminated transcript coding for p.V33Sfs*57.
The p.F35Lfs*2, p.I34Dfs*10 and p.V33Sfs*57 transcripts are
all predicted to be subject to exon junction complex (EJC)
nonsense-mediated mRNA decay (NMD).
FIGURE 1. Transcript analysis of AIPL1 variations mapping within exons or introns close to or within intron/exon boundaries in LCA patients. (A)
AIPL1 genomic structure of the longest AIPL1 transcript (RefSeq NM_014336). The exons (1–6) and introns (I1–I5) are numbered from the 50 to the
30 untranslated region (UTR). (B) Minigene 1 encompasses the entire AIPL1 sequence from exon 1 to 4 amplified from patient gDNA, with the
exception of a large central part of intron 2. Minigene 2 encompasses the entire AIPL1 sequence from exon 3 to 5. Minigene 3 encompasses the
entire AIPL1 sequence from exon 4 to 6 as well as a small region of the 30 UTR. The corresponding minigenes from the wild-type allele were used as
the control for transcript analysis. Arrows indicate the positions of the AIPL1 variations under investigation. (C) Transcript analysis. AIPL1 cDNA
transcripts obtained from the minigene assay were PCR amplified and resolved on 2% to 3% agarose gels. Sanger sequencing was used to confirm the
sequence identity and integrity of the resultant amplicons. The molecular weight markers are in base pairs, and the bands analysed are numbered
(see Table 3).
AIPL1 Missplicing in LCA IOVS j December 2015 j Vol. 56 j No. 13 j 7788
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/934740/ on 03/22/2018
Variations at the 50 end of intron 2 (c.276þ1G>A and
c.276þ2T>C) induce skipping of exon 2, leading to in-frame
deletion of 60 residues from the FKBP-like domain, p.V33_I92-
del (DEx2), and disruption of the putative farnesyl binding
motif. Interestingly, skipping of exon 2 induced by
c.276þ1G>A and c.276þ2T>C also couples with the native
skipping of exon 3 to create a large 122-residue in-frame
deletion of almost the entire FKBP-l ike domain,
p.V33_Q155del (DEx2þ3). The c.276þ1G>A and c.276þ2T>C
variations also induce aberrant transcripts coding for
p.V33_I92delV156Efs*50 and p.H93Afs*66, respectively, both
of which are predicted to be degraded by NMD.
Interestingly, the c.277-2A>G variation at the 30 end of
intron 2 induces only a single aberrant transcript coding for
p.H93_Q155del (DEx3). Similarly, the most abundant splice
product induced by the c.465G>T variation skips exon 3
producing p.H93_Q155del (DEx3). The c.465G>T variation
additionally induces transcription of a longer minor aberrant
TABLE 3. AIPL1 Minigene Splice Products
Mutation (Minigene #) Band # Size, bp Observed Splicing Effect Predicted Protein Suppl. Fig.
w/t (1) 1 652 w/t w/t n/a
2 463 Exon 3 skipped p.H93_Q155del (DEx3) S2
c.97_104dup (1) 3 670 None - duplication retained (frame-shift) p.F35Lfs*2 S3
4 606 Native intron 1 splice acceptor-site not recognized,
cryptic splice acceptor-site at c.142 activated
initial 46 bp of exon 2 skipped (frameshift)
pV33Sfs*57 S4
c.98_99insTGATCTTG (1) 5 670 None - insertion retained (frame-shift) p.I34Dfs*10 S5
6 606 Native intron 1 splice acceptor-site not recognized,
cryptic splice acceptor-site at c.142 activated -
initial 46 bp of exon 2 skipped (frameshift)
pV33Sfs*57 S6
c.276þ1G>A (1) 7 617 Native intron 2 splice donor-site not recognized -
exon 2 skipped, cryptic 145 bp exon 3a inserted
between exons 3 and 4 (frame-shift)
p.V33_I92del V156Efs*50 S7a & S7b
8 472 Native intron 2 splice donor-site not recognized -
exon 2 skipped
p.V33_I92del (DEx2) S8
9 283 Native intron 2 splice donor-site not recognized -
exons 2 and 3 skipped
p. V33_Q155del (DEx2þ3) S9
c.276þ2T>C (1) 10 656 Native intron 2 splice donor-site not recognized,
cryptic splice donor-site 5 bp into intron 2 at
c.276þ5 activated - 4 bp of intron 2 retained
(frame-shift)
p.H93Afs*66 S10
11 472 Native intron 2 splice donor-site not recognized -
exon 2 skipped
p.V33_I92del (DEx2) S11
12 283 Native intron 2 splice donor-site not recognized -
exons 2 and 3 skipped
p. V33_Q155del (DEx2þ3) S12
c.277-2A>G (1) 13 463 Native intron 2 splice acceptor-site not recognized -
exon 3 skipped
p.H93_Q155del (DEx3) S13
c.465G>T (1) 14 439 Native intron 3 splice donor-site not recognized,
cryptic splice donor-site at c.442 activated - last
24 bp of exon 3 skipped
p.V148_Q155del S14
15 463 Native intron 3 splice donor-site not recognized -
exon 3 skipped
p.H93_Q155del (DEx3) S15
w/t (2) 16 520 w/t w/t n/a
c.642G>C (2) 17 499 Native intron 4 splice donor-site not recognized,
cryptic splice donor-site 22 bp into intron 4 at
c.642þ22 activated - 21 bp of intron 4 retained
p.K214N_E215insVRGRWPG S16
18 343 Native intron 4 splice donor-site not recognized -
exon 4 skipped
p.V156_K214del (DEx4) S17
w/t (3) 19 797 w/t w/t n/a
c.784G>A (3) 20 757 Native intron 5 splice donor-site not recognized,
cryptic splice donor-site c.745 activated - last 40
bp of exon 5 skipped (frame-shift)
p.V249Afs*3 S18
21 655 Native intron 5 splice donor-site not recognized -
exon 5 skipped (frame-shift)
p.E215Afs*3 S19
c.785-10_786del (3) 22 1569 Native intron 5 splice acceptor-site not recognized -
intron 5 not spliced out (frame-shift)
p.I263Afs*9 S20
23 755 Native intron 5 splice acceptor-site not recognized,
cryptic acceptor-site at c.826 activated - initial 42
bp of exon 6 skipped
p.G262_A275del S21
24 687 Native intron 5 splice acceptor-site not recognized,
cryptic acceptor-site at c.894 activated - initial
110 bp of exon 6 skipped (frame-shift, read
through into 30UTR)
p.G262Efs*109 S22
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splice product leading to an in-frame deletion of 8 residues in
the FKBP-like domain at its C-terminus, p.V148_Q155del.
The c.642G>C AIPL1 variation generates two aberrant
splice products from minigene 2. The smaller 343 bp product
skips exon 4 leading to the in-frame deletion of the last nine
residues of the FKBP-like domain and the first TPR motif of the
TPR domain, p.V156_K214del (DEx4). The larger 499 bp splice
product results in the in-frame insertion of seven amino acids
in the loop region connecting the first and second TPR motifs
in the TPR domain, p.K214N_E215insVRGRWPG.
Two aberrant splice products are observed for the
c.784G>A AIPL1 variation in minigene 3, both of which result
in a frame-shift and premature translation termination
(p.V249Afs*3 and p.E215Afs*3). The less abundant 655 bp
transcript coding for p.E215Afs*3 is predicted to be cleared by
NMD. The more abundant 757 bp transcript producing
p.V249Afs*3 may escape NMD resulting in C-terminal trunca-
tion of AIPL1 including half of the TPR domain and the entire
polyproline-rich domain (PRD).
The c.785-10_786del mutation in minigene 3 generates
three aberrant splice products that lead to premature
termination (p.I263Afs*9), a 14 amino acid deletion in the
TPR domain (p.G262_A275del), and a frame-shift read-through
into the 30UTR (p.G262Efs*109), respectively.
Alternative Transcription of AIPL1 in Normal
Retina
Analysis of the RNA-seq dataset publically available through
Illumina’s Human BodyMap 2.0 project confirmed that AIPL1 is
FIGURE 2. Splice site products identified by transcript analysis of AIPL1 variations. The genomic structure of the longest AIPL1 transcript (RefSeq
NM_014336) is shown for w/t AIPL1. The transcripts are numbered according to the band number (B#2 to B#24) of the corresponding PCR
amplicon in Figure 1C. The AIPL1 variations are demarcated by an arrowhead according to their position in the AIPL1 gene. The resultant
predicted AIPL1 protein encoded by each transcript is shown above each transcript. Skipped coding sequence (deletions) and retained intron
sequence (insertions) are demarcated by gray and hatched bars, respectively. The sequence data for each transcript is shown in Supplementary
Figures S2 through S22. Scale bar: 500 bp.
AIPL1 Missplicing in LCA IOVS j December 2015 j Vol. 56 j No. 13 j 7790
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/934740/ on 03/22/2018
FIGURE 3. AIPL1 protein isoforms encoded by alternative AIPL1 transcripts. White bars: AIPL1 amino-terminal FKBP-like domain (residues 1–165).
The putative farensyl binding motif encompasses residues 89 to 147. Gray bars: carboxy-terminal TPR domain (residues 171–314). The TPR domain
encompasses three consecutive TPR motifs, TPR1 (178–211), TPR2 (230–263), and TPR3 (264–297). Each TPR motif consists of a pair of antiparallel
a helices (helix A and helix B), and the contiguous series of antiparallel a helices pack against one another to form a chaperone binding channel.
Black bars: primate-specific polyproline-rich domain (PRD) (residues 328–384). Hatched bars: inclusion of nonnative AIPL1 sequence induced by a
frame-shift variation. Bar filled with small squares: in-frame AIPL1 insertion. The transcripts encoding the splice products p.V33Sfs*57,
p.I34Dfs*10, p.F35Lfs*2, p.V33_I92delV156Efs*50, p.H93Afs*66, and p.E215Afs*3 are predicted to be degraded by NMD.
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expressed specifically in the retina and pineal gland, and is not
expressed in any of the 16 tissue types included in the dataset,
including blood, brain, and testes. Annotation of AIPL1 on the
Ensembl database (in the public domain, http://www.ensembl.
org) shows 11 alternative AIPL1 transcripts, one of which is
subject to NMD (AIPL1-007; transcript ID: ENST00000381128).
The normally spliced 6 exon wild-type transcript is annotated
as AIPL1-001 (transcript ID: ENST00000381129), while a splice
variant lacking exon 3 is annotated as AIPL1-002 (transcript ID:
ENST00000250087). However, the relative abundance and
physiological relevance of these alternative transcripts is
unknown. Analyses of RNA-seq data from three retina-derived
datasets23 confirmed that alternative splicing of the AIPL1 gene
occurs in normal retina. Quantitative multisample visualization
of the three independent mRNA sequencing reads aligned to
gene annotations (Sashimi plot) using IGV-2.3.40 (Broad
Institute)24,25 revealed that differential splicing of the AIPL1
gene normally includes skipping of exon 2 (DEx2), exon 3
(DEx3), and exon 4 (DEx4; Supplementary Fig. S1). The
transcript abundance from all three datasets was estimated at
87% (95% confidence interval [CI] ¼6 0.7) for the full-length
transcript (NM_014336.3), 9.7% (95% CI¼6 1.0) for the DEx3
transcript (NM_001033054.1), and 3.4% (95% CI ¼6 0.4) for
the DEx2 transcript (NM_001033055.1). Skipping of exon 4
(DEx4) appears to be a rare event and was detected in only one
of the three independent datasets with the greatest coverage.
Of note, the two splice products detected from w/t minigene 1
in the in vitro splicing assay correspond to the two most
frequently observed RNA-seq transcripts.
DISCUSSION
This study describes the detailed investigation of uncharac-
terized exonic and intronic AIPL1 variations predicted to alter
the normal splicing of the AIPL1 gene in LCA patients.7,16 A
caveat of our findings is the limitations inherent in the in vitro
approach, however in the absence of patient derived RNA or
protein, the in vitro minigene splicing assays have proven
vitally important for validating the theoretical predictions and
supporting the clinical findings. Our data demonstrates that all
nine AIPL1 mutations investigated cause aberrant pre-mRNA
splicing to produce transcripts predicted to be degraded by
NMD and/or encode functionally deficient protein isoforms.
Our findings thus confirm that aberrant alternative transcrip-
tion of the AIPL1 gene may be an underlying cause of LCA.
Our study is the first to show that the AIPL1 missense
mutations c.465G>T [p.(Q155H)], c.642G>C [p.(K214N)] and
c.784G>A [p.(G262S)] alter AIPL1 splicing, a novel finding as
alternative transcription from missense mutations is frequently
overlooked as a potential disease mechanism. The AIPL1
variation c.784G>A [p.(G262S)] is considered a possible rare
benign variant.7,11 However, our in vitro splice assay revealed
that transcription of c.784G>A [p.(G262S)] yields only
p.E215Afs*3 and p.V249Afs*3 variants and no p.G262S. While
the p.E215Afs*3 transcript is expected to be degraded by NMD,
the more abundant transcript producing p.V249Afs*3 may
escape NMD, resulting in truncation of the chaperone-
interacting TPR domain and the loss of the PRD. Our new
findings support the prediction that c.784G>A [p.(G262S)] is a
rare loss-of-function disease-associated mutation. Similarly, both
c.465G>T [p.(Q155H)] and c.642G>C [p.(K214N)] missense
mutations alter AIPL1 transcription in vitro yielding aberrant
splice products that disrupt the domain organization of the
AIPL1 protein. In all cases, correctly spliced transcripts were
not detected. Thus, a complex disease mechanism acting
through the disruption of protein function by aberrant splicing
rather than a simple amino acid substitution exists for these
three missense mutations.
Our analysis also reveals that alternative transcription of
AIPL1 occurs normally in the retina, producing transcripts that
lack exon 2, 3, or 4 as a result of deletion of these 0-0 phase
exons. Interestingly, several of the disease-associated AIPL1
variations investigated in this study also produced transcripts
lacking exon 2, 3, or 4. Both c.276þ1G>A and c.276þ2T>C
induced in-frame skipping of exon 2 to produce p.V33_I92del
(DEx2), c.277-2A>G and c.465G>T [p.(Q155H)] induced in-
frame skipping of exon 3 to produce p.H93_Q155del (DEx3),
and c.642G>C [p.(K214N)] induced skipping of exon 4 to
produce p.V156_K214del (DEx4). Notably, in-frame skipping
of exon 3 was also detected as a minor transcript from wild-
type AIPL1 in the in vitro splice assay, and a low abundance of
the transcript was also detected in vivo in normal retina.
Therefore the splice variants c.277-2A>G and c.465G>T
[p.(Q155H)] shift the relative abundance of this transcript in
retina. Interestingly, the c.465G>T [p.(Q155H)] mutation was
recently identified as a homozygous mutation in all affected
members of a consanguineous family diagnosed with autoso-
mal recessive retinal degeneration, with heterozygous carriers
being unaffected.15 It is therefore possible that there is a
tolerance threshold for expression of this naturally occurring
alternatively spliced AIPL1 transcript, and that the expression
of this transcript in the homozygous state may be associated
with a less severe disease phenotype. Similarly, there may
normally be a tolerance threshold for expression of the
p.V33_I92del (DEx2) and p.V156_K214del (DEx4) alternative
transcripts.
Analyses of the predicted impact of aberrant splicing on the
AIPL1 protein suggest that all of the AIPL1 variations
investigated in this study are invariably loss-of-function
mutations. To summarize (Fig. 3), alternative aberrant tran-
scripts of AIPL1 that shift the open reading frame and lead to
early premature termination are predicted to be degraded by
NMD and are loss-of-function mutations. However, alternate
aberrant transcripts of AIPL1 that involve in-frame exon
skipping, and therefore in-frame deletion of specific domains
within the AIPL1 protein escape NMD, and are likely to exhibit
functional deficits associated with the domain-specific dele-
tion. In-frame skipping of exon 2 or exon 3 disrupts the FKBP-
like domain of AIPL1 leaving the TPR domain intact, whilst
skipping of exon 4 primarily disrupts the TPR domain leaving
the FKBP-like domain intact. The observation that skipping of
exons 2, 3, and 4 normally occurs in the retina, albeit a rare
occurrence, suggests that low levels of expression of alterna-
tive AIPL1 transcripts lacking exons 2, 3, or 4 are normally
tolerated in the retina. However, our data suggest that the
exclusive or abundant expression of alternative AIPL1 tran-
scripts lacking exons 2, 3, or 4 as a result of splice site
variations lead to pathogenesis. Variants affecting the splicing
of exons 5 and 6 of AIPL1, which are out-of-phase, result in
truncation or disruption of the TPR domain and PRD leaving
the FKBP-like domain intact. Because the PRD and a significant
proportion of the TPR domain are encoded by exon 6, many of
the resultant transcripts likely escape NMD to express a faulty
protein unable to interact with the molecular chaperones.
In conclusion, our data has identified aberrant transcription
of AIPL1 as a potential underlying cause of LCA. The analysis
has been important in solving the molecular mechanism of
disease in LCA patients harboring these variations and has
increased our understanding of the role of aberrant RNA
processing as a cause of LCA associated with variations in
AIPL1. This opens up the possibility that a number of
previously uncharacterized AIPL1 variations of unknown
pathogenicity may cause aberrant splicing of AIPL1. Moreover,
unidentified variations in the promoter, untranslated regions,
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cis-acting elements or regulatory elements in the introns or
exons, such as splicing enhancers and silencers, may affect
gene expression, RNA stability, or splicing and contribute to
disease. It is therefore possible that the prevalence of LCA
attributed to AIPL1 mutations may be higher than previously
estimated. Confirmation of this proposal would require further
investigation and screening of AIPL1 in patients with retinal
degeneration and LCA, in combination with in-depth investi-
gations of the effect of newly identified AIPL1 variations at the
transcript and protein level.
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